共 50 条
Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa
被引:218
|作者:
Boulle, Andrew
[1
]
Van Cutsem, Gilles
[1
,2
]
Hilderbrand, Katherine
[1
,2
]
Cragg, Carol
[3
]
Abrahams, Musaed
[2
]
Mathee, Shaheed
[3
]
Ford, Nathan
[1
,2
]
Knight, Louise
[2
]
Osler, Meg
[1
]
Myers, Jonny
[1
]
Goemaere, Eric
[2
]
Coetzee, David
[1
]
Maartens, Gary
[4
]
机构:
[1] Univ Cape Town, Sch Publ Hlth & Family Med, ZA-7925 Cape Town, South Africa
[2] Prov Govt Western Cape, Med Sans Frontiers, Cape Town, South Africa
[3] Prov Govt Western Cape, Dept Hlth, Cape Town, South Africa
[4] Univ Cape Town, Div Clin Pharmacol, Dept Med, ZA-7925 Cape Town, South Africa
来源:
关键词:
antiretroviral therapy;
cohort study;
death registries;
HIV;
loss to follow-up;
resource-limited settings;
South Africa;
TO-CHILD TRANSMISSION;
DISTRICT-WIDE PROGRAM;
SUB-SAHARAN AFRICA;
RAPID SCALE-UP;
CD4 CELL COUNT;
VIROLOGICAL FAILURE;
FOLLOW-UP;
INCOME COUNTRIES;
VIRAL LOAD;
THERAPY;
D O I:
10.1097/QAD.0b013e328333bfb7
中图分类号:
R392 [医学免疫学];
Q939.91 [免疫学];
学科分类号:
100102 ;
摘要:
Objectives: We report on outcomes after 7 years of a community-based antiretroviral therapy (ART) programme in Khayelitsha, South Africa, with death registry linkages to correct for mortality under-ascertainment. Design: This is an observational cohort study. Methods: Since inception, patient-level clinical data have been prospectively captured on-site into an electronic patient information system. Patients with available civil identification numbers who were lost to follow-up were matched with the national death registry to ascertain their vital status. Corrected mortality estimates weighted these patients to represent all patients lost to follow-up. CD4 cell count outcomes were reported conditioned on continuous virological suppression. Results: Seven thousand, three hundred and twenty-three treatment-naive adults (68% women) started ART between 2001 and 2007, with annual enrolment increasing from 80 in 2001 to 2087 in 2006. Of 9.8% of patients lost to follow-up for at least 6 months, 32.8% had died. Corrected mortality was 20.9% at 5 years (95% confidence interval 17.9-24.3). Mortality fell over time as patients accessed care earlier (median CD4 cell count at enrolment increased from 43 cells/mu l in 2001 to 131 cells/mu l in 2006). Patients who remained virologically suppressed continued to gain CD4 cells at 5 years (median 22 cells/mu l per 6 months). By 5 years, 14.0% of patients had failed virologically and 12.2% had been switched to second-line therapy. Conclusion: At a time of considerable debate about future global funding of ART programmes in resource-poor settings, this study has demonstrated substantial and durable clinical benefits for those able to access ART throughout this period, in spite of increasing loss to follow-up. (C) 2010 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins
引用
收藏
页码:563 / U1
页数:11
相关论文